ridinilazole

A narrow-spectrum antibiotic against CLOSTRIDIOIDES DIFFICILE INFECTION.

Also Known As:

(2,2' bis(4-pyridyl) 3H,3'H 5,5' bibenzimidazole; 2,2'-dipyridin-4-yl-1h,1'h-5,5'-bibenzimidazole; SMT19969

Networked: 14 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - ridinilazole: 14
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - ridinilazole: 14

Experts

1.	Vickers, Richard J: 4 articles (01/2020 - 01/2015)
2.	Vickers, Richard: 3 articles (08/2015 - 10/2014)
3.	Mann, John: 2 articles (01/2022 - 08/2015)
4.	Garey, Kevin W: 2 articles (04/2019 - 08/2016)
5.	Wilcox, Mark H: 2 articles (01/2017 - 08/2016)
6.	Tillotson, Glenn: 2 articles (08/2016 - 02/2015)
7.	Baines, S D: 2 articles (01/2015 - 01/2015)
8.	Freeman, J: 2 articles (01/2015 - 01/2015)
9.	Wilcox, M H: 2 articles (01/2015 - 01/2015)
10.	Baron, Anne: 1 article (01/2022)

Related Diseases

1.	Clostridium Infections 08/05/2015 - "One compound in this class, SMT19969, has recently entered Phase 2 human clinical trials for the treatment of Clostridium difficile infections." 02/25/2015 - "A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections." 04/01/2019 - "Ridinilazole for the treatment of Clostridioides difficile infection." 03/01/2019 - "Ridinilazole: a novel antimicrobial for Clostridium difficile infection." 01/01/2015 - "SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostridium difficile infection (CDI). "
2.	Infections 01/01/2017 - "Ridinilazole is a targeted-spectrum antimicrobial that shows potential in treatment of initial C difficile infection and in providing sustained benefit through reduction in disease recurrence. " 01/01/2015 - "These data show that SMT19969 is highly effective at treating both acute infection and preventing recurrent disease and support continued investigation of SMT19969 as a potential therapy for CDI." 01/01/2017 - "We assessed the safety and efficacy of ridinilazole versus vancomycin for treatment of C difficile infection. " 01/01/2017 - "Participants with signs and symptoms of C difficile infection and a positive diagnostic test result were recruited from 33 centres in the USA and Canada and randomly assigned (1:1) to receive oral ridinilazole (200 mg every 12 h) or oral vancomycin (125 mg every 6 h) for 10 days. " 01/01/2015 - "Similar results were observed for SMT19969 and vancomycin following infection with C. "
3.	Abdominal Pain (Pain, Abdominal) 03/01/2019 - "Nausea (20%) and abdominal pain (12%) were the most commonly reported adverse reactions associated with ridinilazole. "
4.	Nausea 03/01/2019 - "Nausea (20%) and abdominal pain (12%) were the most commonly reported adverse reactions associated with ridinilazole. "
5.	Body Weight (Weight, Body) 10/01/2014 - "At 50 mg/kg of body weight, SMT19969 administered orally once daily for 5 days provided full protection of treated animals on the dosing days and through day 12 against epidemic strains. "

Related Drugs and Biologics

1.	Vancomycin
2.	Anti-Infective Agents (Microbicides)
3.	Anti-Bacterial Agents (Antibiotics)
4.	ridinilazole
5.	Bisbenzimidazole (Hoechst 33258)
6.	DNA (Deoxyribonucleic Acid)
7.	Bile Acids and Salts (Bile Acids)
8.	Benzimidazoles
9.	Fidaxomicin

Related Therapies and Procedures

1.	Therapeutics